奥赛康：子公司与阿诺医药达成1类创新药AN9025项目许可引进协议

Core Viewpoint - Aosaikang (002755) has entered into a licensing agreement with Hangzhou Anuo Biopharmaceutical Technology Co., Ltd. for the exclusive rights to develop, manufacture, and commercialize the innovative drug AN9025 in the designated region [1] Group 1: Licensing Agreement Details - Aosaikang's subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., will pay a one-time, non-refundable, and non-offsettable upfront payment of 35 million RMB to Anuo Biopharma within 10 working days after the agreement takes effect [1] - The total milestone payments for product development, registration, and market launch will not exceed 470 million RMB, with additional payments of up to 1.128 billion RMB tied to sales milestone events [1] Group 2: Product Information - AN9025 is a novel oral pan-RAS inhibitor that can simultaneously bind to activated RAS-GTP and molecular chaperone (Cyclophilin A), effectively inhibiting various types of KRAS, NRAS, and HRAS mutations [1] - The drug is intended for the treatment of RAS-mutant solid tumors and has completed Investigational New Drug (IND) applications in both China and the United States, receiving FDA approval for clinical trials [1] Group 3: Financial Implications - Aosaikang will pay a tiered royalty fee based on annual net sales once the product achieves commercial sales in the licensed region [1]